The role of cytokines following bone marrow transplantation: indications and controversies.
The use of cytokines following bone marrow transplantation has become an area of increasing controversy with specific regard to indication, efficacy and cost. This review will attempt to summarize cytokine data in both adult and pediatric transplantation. Indications for cytokines following transplantation will be presented, as well as suggestions for specific issues that should be addressed in future clinical trials.
Weinthal
J A
JA
D000328:Adult; D016026:Bone Marrow Transplantation; D002648:Child; D017326:Clinical Trials, Phase III as Topic; D004334:Drug Administration Schedule; D004921:Erythropoietin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D006085:Graft Survival / Q000187:drug effects; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D019337:Hematologic Neoplasms / Q000628:therapy; D006410:Hematopoiesis / Q000187:drug effects*; D016298:Hematopoietic Cell Growth Factors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007377:Interleukin-3 / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D009369:Neoplasms / Q000628:therapy; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use
D016298:Hematopoietic Cell Growth Factors; D007377:Interleukin-3; C078524:PIXY321 fusion protein, recombinant; D011993:Recombinant Fusion Proteins; D004921:Erythropoietin; D016178:Granulocyte-Macrophage Colony-Stimulating Factor